Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ATP1A1 | P05023 | 6/20 | 0.34 |
| ▸ | ATP1B1 | P05026 | 6/20 | 0.34 |
| ▸ | ATP1A3 | P13637 | 6/20 | 0.34 |
| ▸ | ATP1B2 | P14415 | 6/20 | 0.34 |
| ▸ | ATP1A2 | P50993 | 6/20 | 0.34 |
| ▸ | ATP1B3 | P54709 | 6/20 | 0.34 |
| ▸ | FXYD2 | P54710 | 6/20 | 0.34 |
| ▸ | ATP1A4 | Q13733 | 6/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23596215 | 0.96 | RET (0.33) | NPC1ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL31495554 | 0.87 | — | — | |
| SCHEMBL8376331 | 0.85 | NPC1 (0.47) | NPC1ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL12832331 | 0.83 | NPC1 (0.39) | NPC1SIGMAR1RETALDH1A1 | |
| SCHEMBL11959195 | 0.79 | ALDH1A1 (0.36) | RETALDH1A1 | |
| SCHEMBL8263033 | 0.79 | ALDH1A1 (0.36) | RETALDH1A1 | |
| SCHEMBL5004352 | 0.78 | RET (0.33) | RET | |
| SCHEMBL5004351 | 0.78 | RET (0.33) | RET | |
| Hydrochloric Acid SCHEMBL4280280 | 0.76 | RET (0.33) | RET | |
| Hydrochloric Acid SCHEMBL4280283 | 0.76 | RET (0.33) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806409-B2 | Imaging methods using 18F-radiolabeled biologics | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220001040-A1 | NOVEL PD-L1 BINDING POLYPEPTIDES FOR IMAGING | BRISTOL-MYERS SQUIBB COMPANY | 2022-01-06 | — | — | US | disclosed |
| US-20190184043-A1 | IMAGING METHODS USING 18F-RADIOLABELED BIOLOGICS | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190184043-A1 | IMAGING METHODS USING 18F-RADIOLABELED BIOLOGICS | FAP, FUCA1, FGF23 | NPC1 3232/4885ATP1A1 3806/4885ATP1B1 3656/4885 |
| US-20220001040-A1 | NOVEL PD-L1 BINDING POLYPEPTIDES FOR IMAGING | PDCD10, PDCD1LG2, CD274 | NPC1 3869/4885ATP1A1 4577/4885ATP1B1 4520/4885 |
| US-11806409-B2 | Imaging methods using 18F-radiolabeled biologics | FCGRT, FAP, FUCA1 | NPC1 3154/4885ATP1A1 3780/4885ATP1B1 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.